Tien Liang BioTech Co (ROCO:4127) Operating Margin %: -18.66% (As of Dec. 2025)


ROCO:4127 Tien Liang BioTech Co Ltd ROCO:4127
38 GF Score
Price NT$64.50
GF Value NT$39.20
Valuation Significantly Overvalued
! 8 Warning Signs
View Full Analysis

What is Tien Liang BioTech Co Operating Margin %?

Tien Liang BioTech Co ROCO:4127 38 Operating Margin % is -18.66% as of Dec. 2025. GuruFocus rates ROCO:4127 with a GF Score™ of 38/100 and a GF Value™ of NT$39.20 (Significantly Overvalued). The stock has 8 warning signs investors should review. Among 955 Drug Manufacturers companies, Tien Liang BioTech Co ranks worse than 73.72% on this metric.

Operating Margin % is calculated as Operating Income divided by its Revenue. Tien Liang BioTech Co's Operating Income for the three months ended in Dec. 2025 was NT$-24.6 Mil. Tien Liang BioTech Co's Revenue for the three months ended in Dec. 2025 was NT$131.7 Mil. Therefore, Tien Liang BioTech Co's Operating Margin % for the quarter that ended in Dec. 2025 was -18.66%.

The historical rank and industry rank for Tien Liang BioTech Co's Operating Margin % or its related term are showing as below:

ROCO:4127' s Operating Margin % Range Over the Past 10 Years
Min: -37.92   Med: -3.71   Max: 11.03
Current: -3.15


ROCO:4127's Operating Margin % is ranked worse than
73.72% of 955 companies
in the Drug Manufacturers industry
Industry Median: 7.45 vs ROCO:4127: -3.15

Tien Liang BioTech Co's 5-Year Average Operating Margin % Growth Rate was 0.00% per year.

Tien Liang BioTech Co's Operating Income for the three months ended in Dec. 2025 was NT$-24.6 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Dec. 2025 was NT$-16.1 Mil.

Warning Sign:

Tien Liang BioTech Co Ltd has recorded a loss in operating income at least once over the past 3 years.


Tien Liang BioTech Co  (ROCO:4127) Operating Margin % Explanation

Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.


Be Aware

Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia’s Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.


Tien Liang BioTech Co Operating Margin % Related Terms


Tien Liang BioTech Co Operating Margin % Historical Data

* Premium members only.

The historical data trend for Tien Liang BioTech Co's Operating Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Tien Liang BioTech Co Operating Margin % Chart

Tien Liang BioTech Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Operating Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 7.52 11.03 4.10 0.15 -3.15

Tien Liang BioTech Co Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
Operating Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -6.03 7.07 -2.00 2.00 -18.66

ROCO:4127 vs ZTS: Operating Margin % Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Tien Liang BioTech Co's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Tien Liang BioTech Co Operating Margin % vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Tien Liang BioTech Co's Operating Margin % distribution charts can be found below:

* The bar in red indicates where Tien Liang BioTech Co's Operating Margin % falls into.


ROCO:4127
38GF Score
Tien Liang BioTech Co Ltd ROCO:4127
Operating Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Tien Liang BioTech Co Operating Margin % Calculation

Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.

Tien Liang BioTech Co's Operating Margin % for the fiscal year that ended in Dec. 2025 is calculated as

Operating Margin %=Operating Income (A: Dec. 2025 ) / Revenue (A: Dec. 2025 )
=-16.142 / 511.793
=-3.15 %

Tien Liang BioTech Co's Operating Margin % for the quarter that ended in Dec. 2025 is calculated as

Operating Margin %=Operating Income (Q: Dec. 2025 ) / Revenue (Q: Dec. 2025 )
=-24.568 / 131.653
=-18.66 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Operating Margin % →
What does a Operating Margin % of -18.66% mean?
Tien Liang BioTech Co (ROCO:4127) has a Operating Margin % of -18.66% as of Dec. 2025. Operating margin is the ratio of total operating income to net sales. View historical data on Tien Liang BioTech Co and its competitors. According to the industry distribution chart, Tien Liang BioTech Co ranks #704 out of 955 companies in the Drug Manufacturers industry, placing it in the top 73.7%.
Is Tien Liang BioTech Co's Operating Margin % too high?
Tien Liang BioTech Co's current Operating Margin % is -18.66%. Based on the distribution chart, Tien Liang BioTech Co ranks #704 out of 955 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Tien Liang BioTech Co has a GF Score™ of 38/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Tien Liang BioTech Co's Operating Margin % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Tien Liang BioTech Co ranks #704 out of 955 companies for Operating Margin %. This places Tien Liang BioTech Co in the lower half of its industry. The industry median Operating Margin % is 7.45. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Operating Margin % for a Drug Manufacturers company?
The median Operating Margin % among Drug Manufacturers companies is 7.45, based on 955 companies in the industry. Companies in the top quartile (top 25%) have a Operating Margin % significantly above this median, while those in the bottom quartile fall well below. However, Operating Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Operating Margin % mean?
A high Operating Margin % can signal that a stock is expensive relative to its fundamentals. Operating margin is the ratio of total operating income to net sales. View historical data on Tien Liang BioTech Co and its competitors. For the Drug Manufacturers industry, the median Operating Margin % is 7.45 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Tien Liang BioTech Co's current Operating Margin % is -18.66%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tien Liang BioTech Co stock overvalued right now?
Based on GuruFocus' analysis, Tien Liang BioTech Co (ROCO:4127) is currently considered Significantly Overvalued. The stock's GF Value™ is NT$39.20, compared to a current price of NT$64.50 — trading 64.5% above its estimated fair value. The current Operating Margin % is -18.66%. Tien Liang BioTech Co's overall GF Score™ is 38/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Operating Margin % calculated?
Operating Margin % is calculated from a company's financial statements. For Tien Liang BioTech Co (ROCO:4127), the current Operating Margin % is -18.66% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Tien Liang BioTech Co (ROCO:4127) Overvalued in 2026?

Based on GuruFocus' analysis, Tien Liang BioTech Co stock appears to be overvalued. The current stock price of NT$64.50 is trading 64.5% above its estimated GF Value™ of NT$39.20. GuruFocus considers Tien Liang BioTech Co to be Significantly Overvalued.

Key valuation signals for ROCO:4127:

  • Operating Margin %: -18.66%
  • GF Value™: NT$39.20 vs. price of NT$64.50 (64.5% above fair value)
  • GF Score™: 38/100 with 8 warning signs

No single metric tells the full story. See the ROCO:4127 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Tien Liang BioTech Co Business Description

Address No. 147, Section 1, Datong Road, 9th Floor, Xizhi District, New Taipei City, TWN
Tien Liang BioTech Co Ltd develops and supplies chemicals, pharmaceutical, and Chinese herbs. It offers products for the treatment of intestinal track disease, osteoporosis, eye drops, cholesterin content, angiosclerosis, and hepatic diseases.
38GF Score

Get the complete analysis for ROCO:4127

Operating Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$64.50
Price
NT$39.20
GF Value